GSK To File H5N1 Pandemic Flu Vaccine In Europe By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial using novel ASO3 adjuvant shows high immune response at low dose of antigen.
You may also be interested in...
Cervarix Adjuvant Could Provide Longer Cancer Immune Response, GSK Says
GSK's AS04 adjuvant demonstrates increased immune memory compared to aluminum adjuvants, such as the one used in Merck's Gardasil HPV vaccine.
GSK Vaccine Manufacturing Plan Alternates Pandemic And Seasonal Flu
Results from one of two Phase I pandemic flu vaccine trials in the third quarter will support accelerated European regulatory efforts.
GSK’s Second Flu Vaccine Would Boost Capacity To 30 Mil. Doses
GSK submits a BLA for FluLaval, acquired as part of its 2005 purchase of ID Biomedical, to FDA March 23.